Gripgo Adverse Reactions

Adverse events from historical clinical trial data are both infrequent and from small patient exposure. Accordingly, events reported from extensive post-marketing experience at therapeutic/labelled dose and considered attributable are tabulated as follows by system class. Due to limited clinical trial data, the frequency of these adverse events is not known (cannot be estimated from available data), but post-marketing experience indicates that adverse reactions to Paracetamol are rare and serious reactions are very rare.
Paracetamol: See Table 1.

Click on icon to see table/diagram/image

Caffeine anhydrous: Adverse reactions identified through post-marketing use with Caffeine anhydrous are listed as follows. The frequency of these reactions is unknown. (See Table 2.)

Click on icon to see table/diagram/image

When the recommended Paracetamol-Caffeine anhydrous dosing regimen is combined with dietary Caffeine anhydrous intake, the resulting higher dose of Caffeine anhydrous may increase the potential for Caffeine anhydrous-related adverse effects such as insomnia, restlessness, anxiety, irritability, headache, gastrointestinal disturbances and palpitations.
Phenylephrine HCl: The following adverse events have been observed in clinical trials with Phenylephrine HCl and may therefore represent the most commonly occurring adverse events. (See Table 3.)

Click on icon to see table/diagram/image

Adverse reactions identified during post-marketing use are listed as follows. The frequency of these reactions is unknown: (See Table 4.)

Click on icon to see table/diagram/image

Chlorphenamine Maleate: See Table 5.

Click on icon to see table/diagram/image